TSX News -
Trillium Therapeutics Advances TTI-621 Into Phase 1b Cohort Expansion Enrollment
TORONTO, ONTARIO–(Marketwired – Nov. 2, 2016) – Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TR), a clinical-stage immuno-oncology company developing innovative therapies for [...]